Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. - Wikidata - awgldk - TriplyDB

Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.

Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.

http://www.wikidata.org/entity/Q45855994

about

Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.The effect of an exercise intervention on aerobic fitness, strength and quality of life in children with haemophilia (ACTRN012605000224628).Estimation of transient increases in bleeding risk associated with physical activity in children with haemophilia.Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients.Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.Need for Prophylactic Treatment in Adult Haemophilia A Patients A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.Outcome measures monitoring physical function in children with haemophilia: a systematic review.Outcome measures in haemophilia: more than just factor levels.Quality of life assessment in haemophilia.Treatment of hemophilia: a review of current advances and ongoing issues Management of haemophilia and its complications in developing countries.Optimizing factor prophylaxis for the haemophilia population: where do we stand?Management of chronic synovitis in patients with hemophilia: with special reference to developing countries.Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy.Prophylaxis in adults with haemophilia.Scoring haemophilic arthropathy on X-rays: improving inter- and intra-observer reliability and agreement using a consensus atlas Optimizing outcomes for patients with severe haemophilia A.Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea.Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s Primary prophylaxis in children with haemophilia.Novel drugs to treat hemophilia.Pathophysiology, diagnosis and prevention of arthropathy in patients with haemophilia.Joint protection in haemophilia.Models of prophylaxis.Hemophilia and prophylaxis.The burden of bleeding in haemophilia: is one bleed too many?Considerations in individualizing prophylaxis in patients with haemophilia A.Factor VIII therapy for hemophilia A: current and future issues.Methods for individualising factor VIII dosing in prophylaxis.Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.Individualizing prophylaxis in hemophilia: a review.Personalized prophylaxis.Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score.Evaluating outcome of prophylaxis in haemophilia: objective and self-reported instruments should be combined.Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.Endodontic management of a haemophilic patient- a clinical perspective Long-standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison of age-matched Danish and Russian patients.

P2860

Q26853631-E76633C4-C365-4EB8-9D33-4E385FA293B4 Q31098999-8C7B8277-B478-42B9-B2DC-F8874E741060 Q33245039-D46553EC-2CEE-4301-8FF7-9C332EE59DB5 Q33346945-2E09F29E-BCA3-478B-B578-CEDCBB5F5D2B Q33634745-7F7BA699-C88C-4289-93EA-2E8C55BFAD7A Q33715399-300BABC1-BA86-4456-99AC-0AD55105C9DD Q34139334-84ACBF0B-82FD-4614-9CF0-0F0A8754514C Q34890523-6B8B9E9E-FF4F-493A-A653-9F2236EFAA70 Q35046841-7B52BE61-C3F8-4275-AB66-4DDE768CCFB2 Q35676998-2261C268-17DD-4491-86EE-2355AA623EAA Q35677000-A9A0631C-D273-4493-A012-A7AA4672FC04 Q35683781-2980240A-E02D-41DA-9EED-957204803F11 Q35848322-4E4DDFF6-D75B-4668-963A-EDE7649A8D19 Q35915686-AB0C0433-F371-4968-B2DC-A109CDCE16DB Q36330376-C4C2E4A3-3FFC-42BE-BEC4-CFCA7B77F82C Q36473108-316A254F-38FA-4635-9B9A-9F20BF988C46 Q36904925-69987EE0-3D5D-426E-B308-CFFC8606F3FC Q36908311-0CD0BD40-1B36-44F4-90D9-4CEC56684791 Q36932769-F9574CDF-E360-44DE-9717-7182FA13B0FE Q37057618-99B1CDA6-444E-4FC2-9FCE-4BF27C29AB06 Q37059203-6F863C0F-7618-48DE-B4A9-4FEC5C9D560A Q37098836-F89CC942-3CE6-4BA4-8AE8-06AED8F924ED Q37119644-95ADDF01-B400-4980-BB8D-818BFD7004B2 Q37775029-8CEA8050-E66C-41A5-9E2F-6E1E1E07FFE1 Q37845930-3DEA7A07-BCA2-4955-87F7-D7429B193AEA Q37912258-1DBDD3A2-D11C-43C1-BC09-F8A49190E073 Q38020979-385A681B-5D25-404D-9CD1-D9E09E94A4D7 Q38056467-15FCD8C4-5327-4376-9109-E4D563D374DF Q38182702-F4A1C62A-8E16-4C17-9A3C-77A790825160 Q38203021-15B00CF6-B414-4338-800B-F4667EE2E40B Q38203350-7A94650D-8A56-4411-8655-1176CE4D9759 Q38222572-7CFDEEED-DE74-4E39-BFAF-157E04917334 Q38227605-FBD31244-1FBB-4386-B28B-C91775BEF1C9 Q38323857-D0583461-F291-4B3B-8FB6-5843DECDA7C1 Q39596251-2CE666B3-0E92-4278-B790-8D476D610509 Q39834857-349C8DE0-6808-451F-AC4D-EF85CCB91C56 Q40013630-DF1100F4-ABF3-4E43-8904-BDA6108D5ABC Q41591597-10BBE01C-8BDC-420E-9695-BECD8BA48EA1 Q41843328-E11DE797-6EB2-4FC4-ACC8-47A6DF06EB02 Q44460074-B72A0C27-2ABC-442B-A820-19320A5BC99E

P2860

Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.

http://www.wikidata.org/entity/Q45855994

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Prophylactic treatment for sev ...... e-dose to a high-dose regimen.

@en

Prophylactic treatment for sev ...... e-dose to a high-dose regimen.

@nl

type

label

Prophylactic treatment for sev ...... e-dose to a high-dose regimen.

@en

Prophylactic treatment for sev ...... e-dose to a high-dose regimen.

@nl

prefLabel

Prophylactic treatment for sev ...... e-dose to a high-dose regimen.

@en

Prophylactic treatment for sev ...... e-dose to a high-dose regimen.

@nl

P1433

Q45855994-99BBF047-8FFE-4B96-85D9-75634955405A

P1476

Q45855994-62B568FC-4B86-408C-84A2-A5D5FEDC1BCA

P2093

Q45855994-0D70A3FB-C8C5-4687-8112-B4C0D7CF7D85

Q45855994-32EC6006-08DB-4FF1-9B05-2F1D52C897C6

Q45855994-7416D316-6574-40F8-8CA0-F0516EAEE016

Q45855994-7EFB4B0E-6443-42D6-BBFA-E2C13A62E35F

Q45855994-E99BA973-EF95-4424-8B7A-EC4D53710AA4

P2860

Q45855994-257D4503-3C0E-4C7A-BA3F-71F9E770DDC0

Q45855994-2F3826FC-B9C9-4C46-BBE1-5495F9823684

Q45855994-4941F13D-DE0E-4A54-80DE-E446766250B1

Q45855994-56E1EE23-3996-44C1-9071-AFFA166A6B51

Q45855994-62F63B3D-9498-4633-9A27-58C53224B333

Q45855994-675B1BC0-FE16-43E2-8992-3A2624AC6EB6

Q45855994-692C27ED-77D0-48C3-A8DA-5205A46FB91A

Q45855994-78C04D24-ABE1-4240-B705-DD5BD966D675

Q45855994-92807ACA-8FAE-46B6-A39F-25F13E6152C3

Q45855994-931448FF-F665-4170-8C15-E0C4DBABC436

P304

Q45855994-40722351-CDA7-4C3B-A5B3-3C319A6102F4

P31

Q45855994-D5FACC32-2C0F-436A-A13A-23D04EF44CCF

P356

Q45855994-1CA92B5A-B81B-4CDE-9C7B-F8535800674D

P433

Q45855994-DB6CF7B9-6828-47F3-95BE-2C898CB39CA7

P478

Q45855994-DFA02F70-D23A-4AEA-B2F4-2A65142C9E6E

P50

Q45855994-B3A8BF80-AB93-4717-92A2-F23C9BECB90D

Q45855994-F9FADEF9-CBFE-482C-9F15-CD9A560EC46E

P577

Q45855994-6EA08559-AB4C-4A7E-B945-A7F8CB2F06D7

P698

Q45855994-CAA02950-464E-4AE8-8A24-8F9DC931A86B

P921

Q45855994-0D154B36-26D1-4082-A965-03A48C1A6B39

P356

J.1365-2516.2002.00694.X

P1433

P1476

Prophylactic treatment for sev ...... te-dose to a high-dose regimen

@en

P2093

D E Grobbee

http://www.w3.org/2001/XMLSchema#string

E Berntorp

http://www.w3.org/2001/XMLSchema#string

H M van den Berg

http://www.w3.org/2001/XMLSchema#string

J Astermark

http://www.w3.org/2001/XMLSchema#string

R Ljung

http://www.w3.org/2001/XMLSchema#string

P2860

Confounding and indication for treatment in evaluation of drug treatment for hypertension.

The Swedish SF-36 Health Survey--I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden.

Haemophilia prophylaxis in young patients--a long-term follow-up.

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.

Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group.

The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994.

Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized.

MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage.

Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries.

Joint evaluation instruments for children and adults with haemophilia.

P304

753-760

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2516.2002.00694.X

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Kathelijn Fischer

Johanna G van der Bom

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12410643

http://www.w3.org/2001/XMLSchema#string

P921